Home
/
Arcadia Biosciences, Inc.
/
Financials
/
Quarterly
Arcadia Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Arcadia Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.30M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$1.46M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$1.20M
May 8, 2025
Q3
2025
Sep 30, 2024
$1.54M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$1.31M
Aug 14, 2025
Q1
2025
Mar 31, 2024
$987.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$1.30M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$1.30M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$1.23M
May 13, 2024
Q3
2023
Sep 30, 2022
$1.57M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$3.86M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$3.22M
May 15, 2023
Q3
2022
Sep 30, 2021
$2.38M
Nov 10, 2022
Q2
2022
Jun 30, 2021
$1.41M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$828.0K
May 12, 2022
Q3
2021
Sep 30, 2020
$314.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$281.0K
Aug 16, 2021
Q1
2021
Mar 31, 2020
$309.0K
May 17, 2021
Q3
2020
Sep 30, 2019
$392.0K
Nov 13, 2020
Q2
2020
Jun 30, 2019
$203.0K
Aug 13, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$214.0K
May 9, 2018
Q3
2017
Sep 30, 2017
$589.0K
Nov 9, 2017
Q2
2017
Jun 30, 2017
$991.0K
Aug 10, 2017
Q1
2018
Mar 31, 2017
$1.02M
May 9, 2018
Q3
2017
Sep 30, 2016
$1.08M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$721.0K
Aug 10, 2017
Q1
2017
Mar 31, 2016
$852.0K
May 10, 2017
Q3
2016
Sep 30, 2015
$1.82M
Nov 10, 2016
Q2
2016
Jun 30, 2015
$1.43M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$815.0K
May 10, 2016
Q3
2015
Sep 30, 2014
$1.50M
Nov 5, 2015
Q2
2015
Jun 30, 2014
$1.31M
Aug 11, 2015
Q1
2015
Mar 31, 2014
$1.38M
Jun 25, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$856.0K
Nov 7, 2025
Q2
2025
Jun 30, 2025
($4.46M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
$2.60M
May 8, 2025
Q3
2025
Sep 30, 2024
($1.61M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
$1.06M
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.42M)
May 8, 2025
Q3
2024
Sep 30, 2023
($2.57M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
$823.0K
Aug 13, 2024
Q1
2024
Mar 31, 2023
($9.38M)
May 13, 2024
Q3
2023
Sep 30, 2022
($2.87M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($3.78M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($4.49M)
May 15, 2023
Q3
2022
Sep 30, 2021
($2.18M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($5.26M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
$2.06M
May 12, 2022
Q3
2021
Sep 30, 2020
($6.39M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($9.69M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
$2.53M
May 17, 2021
Q3
2020
Sep 30, 2019
($14.19M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
$4.24M
Aug 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.15M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($501.0K)
Aug 14, 2025
Q1
2025
Mar 31, 2025
$530.0K
May 8, 2025
Q3
2025
Sep 30, 2024
($1.76M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
$1.98M
Aug 14, 2025
Q1
2025
Mar 31, 2024
($1.59M)
May 8, 2025
Q3
2024
Sep 30, 2023
($1.40M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($1.45M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($3.87M)
May 13, 2024
Q3
2023
Sep 30, 2022
($3.99M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($3.78M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($4.62M)
May 15, 2023
Q3
2022
Sep 30, 2021
($8.71M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($7.68M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($5.33M)
May 12, 2022
Q3
2021
Sep 30, 2020
($7.58M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($6.88M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($5.79M)
May 17, 2021
Q3
2020
Sep 30, 2019
($6.19M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
($4.98M)
Aug 13, 2020